(Photo Courtesy: www.archive.freeenterprise.com)
Teneligliptin is a selective DPP4 inhibitor, which suppresses glucagon release and increases insulin release in the body.
Originally the molecule was created by Japanese pharma firm Mitsubishi Tanabe, which received the marketing authorization in 2012.
India as a country is a home to 65.1 million diabetes patients. By 2035, this value will see a jump to 110 million, according to International Diabetes Federation (IDF) 2014.
Globally, diabetes caused at least $612 billion health expenditure in 2014. About 80 percent of the patients live in the middle- or low-income countries worldwide.
The total market for diabetes medication in India is valued at Rs 6,000 crore. IMS Health estimates that gliptins are valued at Rs 1,258 crore, which is 19 percent of the total market.